Jupiter Neurosciences Sold 11.47M Shares for $3.6M Under SEPA, Outstanding Shares Hit 56.5M
JUNS is trading near its 52-week low of $0.099 (6.8% above the low) on light trading volume (0.2× avg).
Summary
Jupiter Neurosciences sold 11.47 million shares to Yorkville under its SEPA for $3.6 million, bringing total outstanding shares to 56.5 million. The sales occurred between May 14 and July 24, 2026, at deeply discounted prices.
Key Events · Financing and Capital Events · JUNS
-
11.47M Shares Sold Under SEPA
Between May 14 and July 24, 2026, the company issued 11,470,000 shares to Yorkville under the Standby Equity Purchase Agreement, raising $3.6 million in gross proceeds.
-
Deeply Discounted Pricing
Shares were sold at 97% of the lowest daily VWAP during each three-day pricing period, a structure that heavily dilutes existing shareholders at depressed prices.
-
Outstanding Shares Surge to 56.5M
Following the sales, total shares outstanding reached 56,520,143 as of July 28, 2026, representing roughly 20% dilution from the latest round alone.
-
Going Concern and Delisting Risks Persist
The company continues to operate under a going-concern warning and faces Nasdaq delisting; the SEPA remains a critical but dilutive funding source.
Analysis · JUNS · Life Sciences
Jupiter Neurosciences disclosed it sold 11.47 million shares to Yorkville under its SEPA between May 14 and July 24, 2026, raising $3.6 million. The per-share price was 97% of the lowest VWAP during each pricing period — a deeply dilutive structure for a stock trading at $0.1058. With 56.5 million shares now outstanding, the latest round alone represents roughly 20% dilution to prior holders. The company remains under a going-concern warning and faces Nasdaq delisting; this filing confirms it continues to rely on the SEPA for survival funding, further pressuring the share price.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JUNS was trading at $0.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.10 to $1.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.